RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

09 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

02 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

01 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

20 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

14 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

14 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

14 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

22 Sep 2021 09:30:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

21 Sep 2021 17:15:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes

20 Sep 2021 06:30:00 By Nasdaq GlobeNewswire